XXXX . Results of a pilot study utilizing a multiagent treatment protocol.

@entity1 @entity882 @entity7712 @entity1872 @entity205 @entity5934 @entity230 @entity3039 @entity3800 @entity2142
PURPOSE: We evaluate the efficacy of combination medical therapy in the treatment of @entity3039 and AIHA episodes for @entity1 with @entity5934 . @entity1 AND METHODS: Five @entity1 with @entity5934 were followed for a median of 3.8 years and were treated according to our multiagent (IVIG, @entity230 , vinca alkaloids, @entity3800 , and @entity205 ) protocol. RESULTS: All @entity1 initially received IVIG and IV @entity230 for either acute @entity2142 or @entity882 . IV vinca alkaloids and oral @entity1872 were added in three @entity1 for @entity3039 . All responded, but two required frequently repeated vinca alkaloid treatments. Both @entity1 treated with vinca alkaloids for severe @entity2142 responded. Two @entity1 received oral @entity205 for refractory @entity3039 ; one had a transient response. Splenectomy was not included in our regimen. Two @entity1 underwent splenectomy prior to their referral; both required further therapy. In addition, review of the clinical courses of our @entity1 indicate that the @entity7712 may be a prognostic factor for the chronicity of @entity3039 . CONCLUSION: In view of the high relapse rates after splenectomy and the encouraging results of our pilot study, we suggest that medical treatment with combination agents (IVIG, @entity230 , vinca alkaloids, @entity3800 and possibly @entity205 ) may provide a useful therapeutic approach to @entity1 with @entity5934 .
